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Background. Lung transplant is a surgical procedure for end-stage lung disease. Many
factors related to lung donors influence the outcome of transplant. The main aim of this
single-center study was to assess which donor-related and procedure-related factors
would influence the 30-day or hospital mortality of the recipients.
Methods. This retrospective study group consisted of 110 donor-recipient pairs
undergoing lung transplant between 2012 and 2017 (group 1) and 2018 and 2019 (group
2) in Silesian Center for Heart Diseases. Both groups of donor- and procedure-related
factors were included in the analysis: oxygenation index at reporting of the donor, time
donor spent in the intensive care unit (ICU), presence of cardiac arrest while being in
the ICU, donor age, type of transplant, cumulative ischemia time, duration of the
operation, and time of mechanical ventilation.
Results. The type of surgery was significantly associated with an increase in the chance of
death within 30 days. Patients who underwent single lung transplant had a 20.217 times
greater chance of dying within 30 days than patients after double lung transplant (inter-
quartile range, 2.116-193.125).
Conclusions. Single lung transplant increases the risk of death during the first 30 days
after lung transplant, and using lungs from older donors may increase the rate of hospital
mortality. Oxygenation index, sudden cardiac arrest of the donors, and donor time spent in
the ICU do not impact the short-term mortality of lung graft recipients.Disclosures: none
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þ48667288893. E-mail: latos.magdalena93@gmail.comLUNG transplantation is a therapeutic option for pa-tients with certain end-stage lung diseases when all of
the other pharmacologic and surgical measures did not
provide the expected outcome. Although this procedure has
certain risks, they are outweighed by its benefits. Median
survival after lung transplant varies according to the un-
derlying disease. Best results are observed among patients
with cystic fibrosis, as 50% of the patients live 9.5 years [1].
Many factors influence the outcome of transplant. Some of
them are related to the lung donor. In Poland, the majority
of procurements are donations after neurologic determi-
nation of death. Such donors and their physicians face many
challenges, as brain death has adverse effects on theAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
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ion Proceedings, 52, 2133e2137 (2020)potential lung graft [2]. Available literature describes that
features such as donor age, history of diabetes, and tobacco
use may impact the 1-year and 5-year survival [3]. Other
articles report significance of cytomegalovirus antibodies
because they are associated with worse results [4]. Donor
PaO2/fraction of inspired oxygen (FiO2) below 300 mm Hg
at reporting is considered to claim the donor as from0041-1345/20
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does not increase the mortality of the recipient [4,5].
Another group of factors are related to the procedure itself.
Those are type of the procedure (single lung transplant
[SLT] or double lung transplant [DLT]), duration of the
operation, cumulative ischemia time, and duration of
mechanical ventilation. The aim of the study was to assess
which donor-related and procedure-related factors would
influence the 30-day or hospital mortality of the recipients
in a single center.
MATERIALS AND METHODS
This retrospective study group consisted of 110 donor-recipient
pairs undergoing lung transplant in Silesian Center for Heart
Diseases between 2012 and 2017 (group 1, 63 patients) and 2018
and 2019 (group 2, 47 patients). Such division is based on the fact
that at the beginning of 2018 a new approach was implemented by a
new medical team. All of the patients from the 2018 to 2019 period
were DLT recipients, while 21 of patients from 2012 to 2017
underwent the same procedure. Demographic features ofTable 1. Demographic Data Pertaining the Don
Variables 2018-2019
Recipients age, mean (SD), y 36.62
Recipient BMI, mean (SD) 18.78
Recipient pulmonary function at qualification
FEV1, median (IQR), % 24
FVC, mean (SD), % 44.69
6MWD, mean (SD), meters 288.03
Donor age, mean (SD), y 41.36
Donor BMI, mean (SD) 24.18
Donor hemoglobin, mean (SD), g% 11.01
Donor serum creatinine, median (IQR), mg% 1.16
Recipient sex, No. (%)
Female 20
Male 27
Donor sex, No. (%)
Female 16
Male 31





Underlying disease, No. (%)
Chronic obstructive pulmonary disease 6
Cystic fibrosis 26
Interstitial lung disease 4
Idiopathic pulmonary arterial hypertension 3
Combined pulmonary fibrosis and emphysema 0





Langerhans cell histiocytosis 1
Hereditary hemorrhagic telangiectasia 0
Abbreviations: 6MWD, 6-minute walk distance; BMI, body mass index (calculate
expiratory volume in 1 second; FVC, forced vital capacity; IQR, interquartile range.aforementioned groups are presented in Table 1. There were 42
single lung recipients in group 1. Median age of the recipients and
mean age of donors in this group were 35 (SD, 23.5) years and 39
(SD, 14.33) years, respectively. Median body mass index (BMI,
calculated as weight in kilograms divided by height in meters
squared) of the recipients, and mean BMI of donors in the afore-
mentioned groups were 19.63 (SD, 4.86) and 22.76 (SD, 2.6),
respectively. Single lung recipient pulmonary function was also
assessed by means of spirometry and 6-minute walk test. Median
forced expiratory volume in 1 second and forced vital capacity were
30% (SD, 32.82%) and 45% (SD, 26%), respectively. Mean dis-
tance obtained in the 6-minute walk test was 275.19 (SD, 141.95)
meters. Median hemoglobin of the donors was 11.7 (SD, 4.9) g%.
Median serum creatinine of the donors was 1.04 (SD, 0.74) mg%.
The majority of the donors were blood type A (58.53%). The
remaining donors presented the following blood types: O (17.07%),
B (14.67%), and AB (9.73%). The majority of single lung recipients
received transplants because of end-stage chronic obstructive pul-
monary disease (38.5%). The remaining patients became transplant
recipients because of interstitial lung diseases (33%) and idiopathic
pulmonary arterial hypertension (27%). The following donor-
related factors were included in the analysis: oxygenation index ators and Recipients of 2 Described Periods
(Group 2) 2012-2017 (Group 1) P Value
(14.28) 36.74 (14.65) .976
(3.33) 19.06 (4.02) .783
(21) 23 (9.9) .216
(17.81) 47.38 (20.63) .591
(165.8) 329.86 (146.46) .224
(12.56) 42.76 (10.42) .657
(2.53) 24.11 (2.99) .913
(2.39) 11.35 (3.1) .666

























d as weight in kilograms divided by height in meters squared); FEV1, forced
Table 2. Comparison of Procedure-related Parameters Depending on the Year of Surgery
2012-2017 2018-2019
U Z P Value rMedian IQR Median IQR
Length of hospital stay, d 43.00 27.00 40.00 21.00 634.50 1.62 .105 0.18
Mechanical ventilation time, h 22.00 9.26 25.00 6.50 90.00 1.27 .205 0.22
Total procedure time, h 11.50 3.50 13.00 2.25 290.00 2.71 .007 0.34
Total ischemia time, min 742.00 192.00 990.00 233.00 173.50 2.29 .022 0.31
Abbreviations: IQR, interquartile range; r, power of effect; U, Mann-Whitney test result; Z, standardized value.
LUNG TRANSPLANT DONOR-RELATED RISK FACTORS 2135reporting of the donor, time the donor spent in the intensive care
unit (ICU), presence of cardiac arrest while being in the ICU, and
donor age. Analysis also pertains to procedure-related factors such
as type of transplant (single lung vs double lung), cumulative
ischemia time, duration of the operation, and time of mechanical
ventilation since the beginning of the operation until patient was
extubated in the ICU. Patients who underwent retransplant or died
during the procedure were excluded from the study. Some of the
analyses were performed only for DLT. Information is provided in
the text of the results.
Statistical Analysis
Data with normal distribution was presented as mean and standard
deviation. Data not presenting the normal distribution were
presented as median and interquartile range. To answer the
research questions, statistical analyses were carried out using Sta-
tistica 13.3 software (TIBCO Software, Palo Alto, Calif, United
States). With its use, basic descriptive statistics were analyzed along
with Shapiro-Wilk tests, Student t test analysis for independent
samples, Mann-Whitney U test, frequency analysis using Fisher
exact test, and logistic regression analysis using the odds ratio
method. The classic threshold a ¼ .05 was considered the level of
significance.RESULTS
It was decided to assess how the parameters of surgery and
hospitalization differ for patients operated on in 2018 to
2019 and before 2018. Analyses were performed using the
Mann-Whitney U test, comparing hospital stay, surgery
time, extubation time, and total ischemia time in these
groups. The analysis was performed only on patients who
underwent DLT, excluding retransplantation. Detailed
results are provided in Table 2.Table 3. Logistic Regression Coefficien
B SE
Coefficients 1.16 3.22
Donor PO2/FiO2 0.00 0.01
Donor PO2 0.00 0.00
Donor age 0.02 0.04
Donor time spent in ICU 0.12 0.17
DLT vs SLT 1.50 0.58
Donor sudden cardiac arrest 0.02 0.62
Abbreviations: b, regression coefficient; DLT, double lung transplant; FiO2, fraction
standard error; SLT, single lung transplant; UL, upper limit.Patients operated on in 2018 to 2019 are characterized by
a longer surgery time and a longer total ischemia time than
patients operated on before 2018. The strength of the
observed relationships turned out to be moderate. However,
patients operated on during these periods of time did not
differ significantly in terms of hospital stay and time to
extubation. Among patients who underwent DLT before
2018, the 30-day mortality was 4.76%. None of the patients
who had the same type of transplant performed between
2018 and 2019 has died within first 30 days after transplant.
It seems that even though time of the operation and total
ischemia time were statistically significantly longer, they did
not influence the short-term mortality.
In the next stage of the analysis, it was decided to attempt
to construct a model predicting hospital or 30-day mortality.
For this purpose, logistic regression analysis was conducted
using the odds ratio method. The following were selected as
independent variables in the model: donor oxygenation
index, donor oxygen partial pressure, donor age,
donor stay in ICU, type of surgery (SLT or DLT), and
occurrence of sudden cardiac arrest while the donor was in
the ICU.
For the 30-day mortality model, Nagelkerke’s R2 was 0.30.
This indicates a moderate link between the prediction and
actual occurrence of death. Among the independent
variables mentioned above, only the type of surgery was
significantly associated with an increase in the chance of
death within 30 days. Patients who underwent SLT had a
20.217 times greater chance of dying within 30 days than
patients after DLT (interquartile range, 2.116-193.125).
Detailed results are presented in Table 3.
Nagelkerke’s R2 hospital mortality model was 0.33. This




0.999 0.988 1.009 .837
1.000 0.994 1.006 .909
0.981 0.905 1.063 .638
0.888 0.640 1.232 .476
0.049 0.005 0.472 .009
0.961 0.084 11,007 .974
of inspired oxygen; ICU, intensive care unit; LL, lower limit; OR, odds ratio; SE,
Table 4. Logistic Regression Coefficients Predicting In-hospital Death




Donor PO2/FiO2 0.01 0.01 1.006 0.988 1.024 .530
Donor PO2 0.00 0.00 0.998 0.990 1.006 .587
Donor age 0.12 0.06 0.884 0.789 0.990 .033
Donor time spent in ICU 0.35 0.22 0.707 0.458 1.091 .117
DLT vs SLT 0.98 0.64 0.141 0.012 1.703 .123
Donor sudden cardiac arrest 0.29 0.68 0.556 0.039 7.995 .666
Abbreviations: b, regression coefficient; DLT, double lung transplant; FiO2, fraction of inspired oxygen; ICU, intensive care unit; LL, lower limit; OR, odds ratio; SE,
standard error; SLT, single lung transplant; UL, upper limit.
2136 URLIK, STĄCEL, LATOS ET ALoccurrence of death. Of the independent variables listed
above, only donor age was significantly associated with
an increase in the chance of death during hospitalization. A
1-year decrease in donor age was associated with a
1.131 times greater chance of death (interquartile range,
1.010-1.267). Detailed data are shown in Table 4.DISCUSSION
Systemic review performed by Almasri et al was conducted to
assess the recipient- and donor-related risk factors of death
after transplant. In this review, authors analyzed 81 papers. No
donor-related risk factors influencing the outcome of lung
transplantation was found [6]. However, there are some
recipient-related factors. Our study assessed that SLT is
associated with worse outcome and increases the risk of death
in the first 30 days post operation. Furthermore, this finding is
consistent with the International Heart and Lung Trans-
plantation Registry in reporting long-term survival. Median
survival after SLT is 3 years shorter thanDLT (4.8 vs 7.8 years,
respectively). Such result is even more prominent when con-
ditional median survivals are compared (10.2 years for DLT vs
6.5 years for SLT). DLT is also described to be superior for
recipients with high lung allocation score by Black et al [7].
This means that patients with more severe condition who
require urgent transplant will benefit more from a pair of new
lungs instead of just 1. On the other hand, work published by
Aryal and Nathan suggest that the quality of the evidence
supporting the superiority of bilateral lung transplant among
patients with chronic obstructive pulmonary disease and pul-
monary fibrosis is low in the absence of prospective studies [8].
While assessing the hospital mortality, our study showed that
the risk of death is greater among patients whose donors were
younger. This finding is particularly interesting and requires
further research because studies suggest otherwise or that the
age of the donor is not as significant as it was previously
thought. Toour knowledge, there is no studywith similar result
and none of them offer any explanation of our result. One of
our theories is that older lungs are more immune to ischemia.
As lung function deteriorates with advancing age, physiolog-
ical events make the alveolar ducts wider and shallower, and
lung volume increases [9]. Nevertheless, gas exchange is
remarkably well preserved despite the reduced alveolar sur-
face area and increased ventilation-perfusion heterogeneity[10]. It was established that the cutoff age for lung donors was
55 years or younger. Therefore, more liberal criteria regarding
age could be implemented.
Data from International Heart and Lung Trans-
plantation Registry suggest that donor age is associated
with increased 10-year mortality, but hazard ratio for this
analysis does not seem strong or even moderate. Whited
et al performed the study that assessed the effect of lungs
from donors older than 60 years on the survival. Their
research showed that donor lungs aged 60 years or more
were associated with slightly worse 5-year survival, but
among double lung recipients, there was no statistically
significant difference in survival after stratification for
young and old recipients [11]. Nevertheless, SLT showed
significantly worse results and according to their study
should not be performed in case of lungs from older do-
nors. Finally, our analysis proved that oxygenation index of
the donor does not influence the short-term survival of the
recipients. This finding is consistent with the article pub-
lished by Chaney et al, who claimed that PaO2/FiO2 ratios
less than 300 mm Hg should not dissuade donor organ use
[12]. During the time, when an increase of number of po-
tential candidates is accompanied by a decrease of reported
donors, information that relatively low oxygenation index
will not contribute to recipient mortality allows the
extension of the donor pool. Hence, more patients will have
a chance for receiving a graft. Efforts made by our team led
to the acceptance of 300 mm Hg as the new lower limits of
donor oxygenation index instead of 400 mm Hg
among lung transplant centers in Poland. Our study group
also has 2 recipients whose donor lung oxygenation indexes
were 272 mm Hg and 290 mm Hg. Other studies by Zafar
et al and Zych et al support the approach that carefully
selected donors with PaO2/FiO2 below 300 mm Hg
can have their lungs procured for safe transplant [13,14].
They both reached 1-year survival and are alive and well.CONCLUSIONS
SLT increases the risk of death during the first 30 days after
lung transplant. This study assessed that using lungs from
older donors may have a positive effect on hospital
mortality. This finding requires further study because to the
authors’ knowledge it was not presented anywhere else. It is
LUNG TRANSPLANT DONOR-RELATED RISK FACTORS 2137important that oxygenation index, sudden cardiac arrest of
the donors, and donor time spent in the ICU does not
impact the short-term mortality of the lung graft recipients.
These findings support the idea of the donor pool extension
by applying the more liberal criteria.
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